Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PPL002
MIFTS: 47

Papillary Carcinoma

Categories: Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Papillary Carcinoma

About this section

MalaCards integrated aliases for Papillary Carcinoma:

Name: Papillary Carcinoma 12 15 17
Carcinoma, Papillary 43 71
Carcinoma Papillary 54

Classifications:

MalaCards categories:
Global: Cancer diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:3113
MeSH 43 D002291
NCIt 49 C2927
SNOMED-CT 67 25910003
UMLS 71 C0007133
Sources

Summaries for Papillary Carcinoma

About this section
Disease Ontology : 12 A carcinoma that is derives from epithelial cells with finger like projections.

MalaCards based summary : Papillary Carcinoma, also known as carcinoma, papillary, is related to breast papillary carcinoma and primary peritoneal carcinoma. An important gene associated with Papillary Carcinoma is TG (Thyroglobulin), and among its related pathways/superpathways are Gastric cancer and Endometrial cancer. The drugs Sorafenib and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include thyroid, breast and lymph node, and related phenotypes are behavior/neurological and cellular

Sources

Related Diseases for Papillary Carcinoma

About this section

Diseases related to Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 719)
# Related Disease Score Top Affiliating Genes
1 breast papillary carcinoma 34.5 PGR ESR1 ERBB2
2 primary peritoneal carcinoma 34.3 RET PGR ERBB2
3 tall cell variant papillary carcinoma 34.0 TG RET NKX2-1 MET LGALS3 KRT19
4 multicentric papillary thyroid carcinoma 33.3 TG RET
5 nonencapsulated sclerosing carcinoma 33.0 TPO TG RET CALCA
6 papillary serous adenocarcinoma 32.9 PGR PAX8 NKX2-1 KRT7 KRT20
7 renal cell carcinoma, nonpapillary 32.8 RET PAX8 NKX2-1 MUC1 MET KRT7
8 thyroid cancer, nonmedullary, 2 32.5 TSHR TG PAX8 LGALS3 CALCA BRAF
9 in situ carcinoma 31.5 PGR MUC1 ESR1 ERBB2
10 ductal carcinoma in situ 31.4 PGR MUC1 ESR1 ERBB2
11 thyroid tumor 31.2 TPO TG RET LGALS3 BRAF
12 parathyroid adenoma 31.2 RET LGALS3 CALCA
13 thyroid carcinoma, familial medullary 31.0 TG RET NKX2-1 CALCA BRAF
14 papillary adenocarcinoma 31.0 PGR NKX2-1 MUC1 KRT7 KRT19 ERBB2
15 adenoma 31.0 TSHR TG RET MUC1 LGALS3 KRT7
16 thyroid carcinoma 31.0 TSHR TPO TG RET NKX2-1 NCOA4
17 intraductal papilloma 30.9 PGR KRT7 ESR1 ERBB2
18 hyperthyroidism 30.9 TSHR TPO TG CALCA
19 benign mesothelioma 30.9 PAX8 KRT7
20 transitional cell carcinoma 30.8 KRT7 KRT20 KRT19 ERBB2 BRAF
21 graves' disease 30.8 TSHR TPO TG PAX8
22 metanephric adenoma 30.8 MUC1 KRT7 BRAF
23 graves disease 1 30.7 TSHR TPO TG CALCA
24 squamous cell carcinoma 30.7 MUC1 KRT7 KRT19 ERBB2 BRAF
25 thymoma 30.7 TG NKX2-1 MUC1 KRT7
26 cystic teratoma 30.7 NKX2-1 KRT7 KRT20
27 thyroiditis 30.7 TSHR TPO TG RET NKX2-1 NCOA4
28 teratoma 30.7 NKX2-1 KRT7 KRT20 ESR1
29 gynecomastia 30.7 PGR ESR1 ERBB2
30 adenocarcinoma 30.7 RET NKX2-1 MUC1 MET KRT7 KRT20
31 endometrial serous adenocarcinoma 30.7 PGR ERBB2 CLDN3
32 biliary papillomatosis 30.6 MUC1 KRT7
33 peritoneal mesothelioma 30.6 PGR MUC1 MET ESR1
34 parathyroid carcinoma 30.6 RET LGALS3 CALCA
35 breast fibroadenoma 30.6 PGR ESR1 ERBB2
36 leiomyosarcoma 30.6 PGR MUC1 ESR1
37 goiter 30.6 TSHR TPO TG RET PAX8 NKX2-1
38 nonseminomatous germ cell tumor 30.6 ERBB2 BRAF
39 pneumothorax 30.6 PGR NKX2-1 MUC1
40 bronchiolo-alveolar adenocarcinoma 30.6 NKX2-1 KRT7 KRT20
41 mature teratoma 30.6 TG KRT7 ERBB2 BRAF
42 mesothelioma, malignant 30.5 NKX2-1 MUC1 MET KRT7 KRT20 KRT19
43 papillary transitional carcinoma 30.5 KRT7 KRT20
44 dysgerminoma 30.5 MUC1 KRT7 KRT20
45 hemangioma 30.5 RET PGR NKX2-1 MUC1 KRT7
46 colloid adenoma 30.5 TG LGALS3
47 thyroid gland medullary carcinoma 30.5 TG RET PAX8 NCOA4 CCDC6 CALCA
48 oncocytoma 30.5 NKX2-1 MUC1 KRT7 KRT20 KRT19
49 intrahepatic cholangiocarcinoma 30.5 MUC1 KRT7 KRT20 KRT19 ERBB2
50 ectopic thymus 30.5 TG NKX2-1 CALCA

Graphical network of the top 20 diseases related to Papillary Carcinoma:



Diseases related to Papillary Carcinoma
Sources

Symptoms & Phenotypes for Papillary Carcinoma

About this section

MGI Mouse Phenotypes related to Papillary Carcinoma:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.37 BRAF CLDN3 ERBB2 ESR1 LGALS3 MET
2 cellular MP:0005384 10.35 BRAF ERBB2 ESR1 KRT19 KRT7 LGALS3
3 homeostasis/metabolism MP:0005376 10.32 BRAF ERBB2 ESR1 KRT7 LGALS3 MET
4 endocrine/exocrine gland MP:0005379 10.29 BRAF ERBB2 ESR1 KRT19 MET NKX2-1
5 growth/size/body region MP:0005378 10.27 BRAF ERBB2 ESR1 KRT19 LGALS3 MET
6 cardiovascular system MP:0005385 10.25 BRAF ERBB2 ESR1 KRT19 LGALS3 MET
7 mortality/aging MP:0010768 10.25 BRAF CCDC6 ERBB2 ESR1 KRT19 LGALS3
8 digestive/alimentary MP:0005381 10.18 BRAF ERBB2 ESR1 KRT19 LGALS3 MET
9 limbs/digits/tail MP:0005371 10.16 BRAF ERBB2 ESR1 MET PAX8 PGR
10 nervous system MP:0003631 10.11 BRAF ERBB2 ESR1 KRT19 LGALS3 MET
11 neoplasm MP:0002006 10.1 BRAF ERBB2 ESR1 KRT19 LGALS3 MET
12 reproductive system MP:0005389 9.93 BRAF CLDN3 ERBB2 ESR1 KRT19 LGALS3
13 normal MP:0002873 9.91 BRAF ERBB2 ESR1 KRT19 MET NKX2-1
14 no phenotypic analysis MP:0003012 9.87 ESR1 KRT19 MET NKX2-1 PAX8 PGR
15 respiratory system MP:0005388 9.56 BRAF ERBB2 ESR1 KRT19 LGALS3 MET
16 skeleton MP:0005390 9.36 BRAF ERBB2 ESR1 KRT19 LGALS3 NKX2-1
Sources

Drugs & Therapeutics for Papillary Carcinoma

About this section

Drugs for Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 91)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
2
Everolimus Approved Phase 3 159351-69-6 70789204 6442177
3
BCG vaccine Investigational Phase 3
4 Adjuvants, Immunologic Phase 3
5 Vaccines Phase 3
6 Immunosuppressive Agents Phase 3
7 Immunologic Factors Phase 3
8 Alkylating Agents Phase 3
9 Anti-Bacterial Agents Phase 3
10 Antibiotics, Antitubercular Phase 3
11 Mitomycins Phase 3
12
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
13
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
14
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
15
leucovorin Approved Phase 2 58-05-9 6006 143
16
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492 6473866
17
Lenograstim Approved, Investigational Phase 2 135968-09-1
18
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
19
Melphalan Approved Phase 2 148-82-3 460612 4053
20
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
21
Durvalumab Approved, Investigational Phase 2 1428935-60-7
22
Ipilimumab Approved Phase 2 477202-00-9
23
nivolumab Approved Phase 2 946414-94-4
24
Trametinib Approved Phase 2 871700-17-3 11707110
25
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
Lenvatinib Approved, Investigational Phase 2 417716-92-8
28
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
29
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
30
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
31
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
32
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
33
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
34
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36
Triamcinolone Approved, Vet_approved Phase 2 124-94-7 31307
37
Gemcitabine Approved Phase 2 95058-81-4 60750
38
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
39
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
40
Tremelimumab Investigational Phase 2 745013-59-6
41
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
42
Maleic acid Experimental, Investigational Phase 1, Phase 2 110-17-8, 110-16-7 444972
43 Vitamin B Complex Phase 2
44 Folic Acid Antagonists Phase 2
45 Folate Phase 2
46 Dermatologic Agents Phase 2
47 Vitamin B9 Phase 2
48 Calcineurin Inhibitors Phase 2
49 Mitogens Phase 2
50 Fluorides Phase 2

Interventional clinical trials:

(show top 50) (show all 77)
# Name Status NCT ID Phase Drugs
1 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
2 Open-label, Multi-center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG Completed NCT00406068 Phase 2, Phase 3 Mycobacterial cell wall-DNA complex
3 Value of Sentinel Lymph Node Biopsy to Lateral Neck Lymph Node in Thyroid Carcinoma: Prospective Study Completed NCT01137097 Phase 2, Phase 3
4 A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ Completed NCT00003779 Phase 3
5 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
6 Sentinel Lymph Node Biopsy in the Thyroid Carcinoma; Randomized, Prospective Study Recruiting NCT01149161 Phase 2, Phase 3
7 EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study Active, not recruiting NCT01120249 Phase 3 everolimus
8 A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC Terminated NCT03335059 Phase 3
9 A Phase II Study of Docetaxel and Carboplatin for Suboptimally Debulked Stage III or Stage IV Ovarian and Fallopian Tube Carcinoma Unknown status NCT00003560 Phase 2 carboplatin;docetaxel
10 A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer Completed NCT00688753 Phase 2 RAD001
11 A Pivotal Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With 131I-Refractory Metastatic Or Unresectable Locally-Advanced Thyroid Cancer Completed NCT00389441 Phase 2 AG-013736
12 A Phase II Study of the c-MET RTK Inhibitor XL880 in Subjects With Papillary Renal-Cell Carcinoma Completed NCT00726323 Phase 2 foretinib (formerly GSK1363089 or XL880)
13 Adoptive Immunotherapy by Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Carcinoma: A Phase II Study Completed NCT00027573 Phase 2 cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
14 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
15 A PHASE I/II TRIAL TO EVALUATE BRACHYTHERAPY AS THE SOLE METHOD OF RADIATION THERAPY FOR STAGE I AND II BREAST CARCINOMA Completed NCT00002873 Phase 1, Phase 2
16 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
17 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
18 Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) ± Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer Completed NCT00182793 Phase 2 carboplatin;cyclophosphamide;melphalan;thiotepa
19 A Single Arm, Multicenter Single Stage Phase II Trial of RAD001 as Monotherapy in the Treatment of Metastatic Non Syndromic Neuro-endocrine Tumors Completed NCT00688623 Phase 2 Everolimus
20 Phase II Study On Paclitaxel In Recurrent Uterine Papillary Serous Carcinoma (UPSC) Completed NCT00022620 Phase 2 paclitaxel
21 Phase II Study of Histone Deacetylase Inhibitor SAHA (Vorinostat) in Patients With Metastatic Thyroid Carcinoma Completed NCT00134043 Phase 2 vorinostat
22 Open Label Phase II Trial of Bendamustine Hydrochloride (HCL) in Women With Advanced Ovarian Cancer Completed NCT00867503 Phase 2 Bendamustine HCL
23 A Phase II Study of Ridaforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer Completed NCT00770185 Phase 2 ridaforolimus
24 Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of Thyroid With Functional Imaging Correlation Completed NCT00519896 Phase 2 sunitinib malate
25 A Phase II Trial of 17-Allylaminogeldanamycin (17AAG) in Advanced Medullary and Differentiated Thyroid Carcinoma Completed NCT00118248 Phase 2 tanespimycin
26 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
27 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
28 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
29 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib S-malate
30 Safety and Feasibility of Accelerated, Hypofractionated Radiotherapy in Women With Breast Cancer: A Phase II Trial Recruiting NCT00909909 Phase 2
31 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Recruiting NCT02152995 Phase 2 Trametinib
32 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
33 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
34 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Recruiting NCT02978625 Phase 2
35 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
36 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Active, not recruiting NCT02973997 Phase 2 Lenvatinib
37 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
38 A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma With Sarcomatoid Features Active, not recruiting NCT01164228 Phase 2 gemcitabine hydrochloride;sunitinib malate
39 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Active, not recruiting NCT02393690 Phase 2 Selumetinib
40 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib;Cediranib Maleate;Lenalidomide
41 Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer Active, not recruiting NCT00295893 Phase 2 carboplatin;cyclophosphamide;docetaxel;doxorubicin hydrochloride;paclitaxel
42 Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma Active, not recruiting NCT01367002 Phase 2 Carboplatin/Paclitaxel;Trastuzumab
43 A Phase II Trial of Gemzar (Gemcitabine) and Gleevec (Imatinib Mesylate) in Patients With Metastatic Renal Cell Carcinoma Terminated NCT00323791 Phase 2 gemcitabine hydrochloride;imatinib mesylate
44 Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary Withdrawn NCT00003865 Phase 2 toremifene
45 A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium Completed NCT00448643 Phase 1 Cisplatin
46 Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Unknown status NCT02648399
47 Efficacy of Shear Wave Ultrasound Elastography in Noninvasive Diagnosis of Thyroid Nodules Unknown status NCT01757834
48 Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy Completed NCT02768753
49 Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma Completed NCT01150318 Administration of 131 iodine
50 Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Completed NCT01927887 Ferumoxytol

Search NIH Clinical Center for Papillary Carcinoma

Cochrane evidence based reviews: carcinoma, papillary

Sources

Genetic Tests for Papillary Carcinoma

About this section
Sources

Anatomical Context for Papillary Carcinoma

About this section

MalaCards organs/tissues related to Papillary Carcinoma:

40
Thyroid, Breast, Lymph Node, Kidney, Lung, Ovary, Pancreas
Sources

Publications for Papillary Carcinoma

About this section

Articles related to Papillary Carcinoma:

(show top 50) (show all 5733)
# Title Authors PMID Year
1
Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. 54 61
20198455 2010
2
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. 61 54
20012784 2010
3
Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. 54 61
20042852 2010
4
Adult onset Still's disease diagnosed concomitantly with occult papillary thyroid cancer: paraneoplastic manifestation or coincidence? 61 54
19847590 2010
5
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. 54 61
19740516 2010
6
BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. 54 61
19738460 2009
7
Papillary carcinoma of the breast lacks evidence of RET rearrangements despite morphological similarities to papillary thyroid carcinoma. 54 61
19543246 2009
8
COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. 61 54
19391129 2009
9
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 54 61
19426958 2009
10
Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. 54 61
19506552 2009
11
The T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma. 61 54
19415957 2009
12
The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. 54 61
19126567 2009
13
Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. 61 54
18996649 2009
14
Differential expression of CK 19 in follicular adenoma, well-differentiated tumour of uncertain malignant potential (WDT-UMP) and follicular variant of papillary carcinoma. 54 61
19213370 2009
15
A case of black thyroid associated with hyalinizing trabecular tumor. 61 54
18753707 2008
16
Coexistence of primary squamous cell carcinoma of thyroid with classic papillary thyroid carcinoma. 54 61
19067856 2008
17
Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. 61 54
18657294 2008
18
Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. 61 54
18248390 2008
19
Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. 54 61
18809382 2008
20
Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. 54 61
18925698 2008
21
Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. 61 54
18795075 2008
22
Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. 54 61
18313739 2008
23
Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration. 61 54
18540296 2008
24
Thyroid carcinoma: molecular pathways and therapeutic targets. 61 54
18437172 2008
25
[A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma]. 61 54
18408444 2008
26
Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction. 61 54
18308654 2008
27
Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. 61 54
18254952 2008
28
HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. 54 61
17451461 2008
29
Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies. 61 54
18688583 2008
30
[Galectin-3 in diagnosis of thyroid cancer]. 61 54
18652236 2008
31
Iodine-123 uptake in vertebral haemangiomas in a patient with papillary thyroid carcinoma. 54 61
19173186 2008
32
Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. 61 54
18677652 2008
33
Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. 61 54
18581271 2008
34
The histological diagnosis of metastases to the breast from extramammary malignancies. 61 54
18042689 2007
35
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. 54 61
17728499 2007
36
h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. 61 54
17667535 2007
37
Immunohistochemical staining of papillary breast lesions. 61 54
17525625 2007
38
Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. 61 54
17409099 2007
39
Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. 61 54
17473695 2007
40
Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). 54 61
17326053 2007
41
Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. 61 54
17295644 2007
42
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. 61 54
16698948 2007
43
Annexin-I as a potential target for green tea extract induced actin remodeling. 61 54
17019707 2007
44
Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. 54 61
16983703 2006
45
The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma. 61 54
16944537 2006
46
Proteomic identification of new biomarkers and application in thyroid cytology. 61 54
17017437 2006
47
New molecular targeted therapies in thyroid cancer. 54 61
16940797 2006
48
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. 54 61
17001889 2006
49
GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma. 54 61
16842248 2006
50
Simultaneous immunohistochemical expression of HBME-1 and galectin-3 differentiates papillary carcinomas from hyperfunctioning lesions of the thyroid. 61 54
16722927 2006
Sources

Variations for Papillary Carcinoma

About this section
Sources

Expression for Papillary Carcinoma

About this section
Search GEO for disease gene expression data for Papillary Carcinoma.
Sources

Pathways for Papillary Carcinoma

About this section

Pathways related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Gastric cancer 36
Show member pathways
 12.5 PGR MET ESR1 ERBB2 BRAF
2
Endometrial cancer 36
Show member pathways
 12.38 RET PAX8 NCOA4 ERBB2 CCDC6 BRAF
3
Cytoskeletal Signaling 4
12.14 MUC1 KRT7 KRT20 KRT19 CLDN3
4
Pathways in cancer 36
11.95 RET PAX8 NCOA4 MET ESR1 ERBB2
5
Proteoglycans in cancer 36
11.93 MET ESR1 ERBB2 BRAF
6
Central carbon metabolism in cancer 36
11.43 RET MET ERBB2
7
Human Thyroid Stimulating Hormone (TSH) signaling pathway 1
11.38 TSHR PAX8 BRAF
8
Thyroxine (Thyroid Hormone) Production 1
9.91 TSHR TPO TG
Sources

GO Terms for Papillary Carcinoma

About this section

Cellular components related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.5 TSHR TPO RET MUC1 MET ERBB2
2 receptor complex GO:0043235 8.92 TSHR RET MET ERBB2

Biological processes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.77 RET NKX2-1 ERBB2 CLDN3 BRAF
2 MAPK cascade GO:0000165 9.73 RET MET ERBB2 BRAF
3 positive regulation of protein kinase B signaling GO:0051897 9.56 RET MET ESR1 ERBB2
4 positive regulation of kinase activity GO:0033674 9.5 RET MET ERBB2
5 peptidyl-tyrosine phosphorylation GO:0018108 9.46 RET MET ERBB2 BRAF
6 hormone biosynthetic process GO:0042446 9.4 TPO TG
7 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 TSHR PAX8
8 thyroid gland development GO:0030878 8.92 TG PAX8 NKX2-1 BRAF

Molecular functions related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.28 TSHR TG RET PGR PAX8 NKX2-1
2 identical protein binding GO:0042802 9.76 TG PGR MET ESR1 ERBB2 CLDN3
3 protein phosphatase binding GO:0019903 9.54 MET LGALS3 ERBB2
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 RET MET ERBB2
5 protein tyrosine kinase activity GO:0004713 9.26 RET MET ERBB2 BRAF
6 thyroid-stimulating hormone receptor activity GO:0004996 8.62 TSHR PAX8
Sources

Sources for Papillary Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....